CONMED Corporation (NYSE: CNMD) is a Healthcare company (Medical - Devices) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
CONMED Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $48.39, CONMED Corporation trades at 20.1x trailing earnings, 1.1x sales and 1.4x book value, with an EV/EBITDA of 10.5. Over the last twelve months it generated about $1.4B of revenue and $72M of net income. It runs a gross margin of 57.2%, an operating margin of 12.1% and a net margin of 5.4%. It shows return on equity of 7.1%, return on invested capital of 5.7% and a free cash flow yield of 9.2%. On the balance sheet: a debt-to-equity ratio of 0.77 and a current ratio of 1.49. Over the past 52 weeks the share price ranged from $31.44 to $54.80, with a beta of 0.90.
CONMED Corporation does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 7 Buy, 13 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, CONMED Corporation (CNMD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 56.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.34% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 56.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.34% / 33% · Receivables / Mkt Cap (36m) 16.3% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 56.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.34% / 33.33% · Receivables / Mkt Cap (24m) 16.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 36.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 1.74% / 33.33% · Receivables / Avg Assets (4Q) 10.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 35.4% / 33.33% · (Cash+ST Inv) / Total Assets 2.08% / 33.33% · (Cash+Recv) / Total Assets 12.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, CONMED Corporation (CNMD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. CONMED Corporation is over the AAOIFI limit on Debt / Mkt Cap (36m).
CONMED Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.